Skip to main content Skip to section navigation Skip to footer

Processa Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Partnering
    • Management Team
    • Board of Directors
  • Product Pipeline
    • Overview
    • PCS3117
    • PCS6422
    • PCS11T
    • Publications
  • Our Clinical Trials
    • Overview
    • PCS6422
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • In The News
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Presentations

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • In The News
Investor Slide Deck – March 2025
Mar 28, 2025

Investor Slide Deck – March 2025

Investor Slide Deck – February 2025
Feb 11, 2025

Investor Slide Deck – February 2025

Investor Presentation
Aug 26, 2024

Investor Presentation

Corporate Presentation
Apr 3, 2024

Corporate Presentation

Corporate Presentation
Mar 1, 2024

Corporate Presentation

Corporate Presentation
Jan 11, 2024

Corporate Presentation

Next Generation Chemotherapy:  Improved Treatment for More Patients
Dec 5, 2023

Next Generation Chemotherapy: Improved Treatment for More Patients

Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial
Nov 16, 2023

Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial

Investor Presentation
Nov 10, 2023

Investor Presentation

Next Generation Chemotherapy:  Improved Treatment for More Patients
Jun 21, 2023

Next Generation Chemotherapy: Improved Treatment for More Patients

RSS
  • 1
  • 2
  • 3
  • Next
Twitter LinkedIn
©2025 Processa Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences